Difference between revisions of "Ziv-aflibercept (Zaltrap)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (PeterYang moved page Aflibercept (Zaltrap) to Ziv-aflibercept (Zaltrap): FDA approval, new name)
m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp")
 
(27 intermediate revisions by 4 users not shown)
Line 1: Line 1:
−
Also known as VEGF trap.  When used for its approved macular degeneration indication, it is known as Eylea.  '''in clinical trials'''
 
−
 
 
==General information==
 
==General information==
−
Class/mechanism: fusion protein that binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PLGF (placental growth factor).  By binding to and inhibiting these angiogenic growth factors, aflibercept is hypothesized to interfere with tumor angiogenesis.<ref>[http://www.regeneron.com/aflibercept Regeneron's Aflibercept site]</ref>
+
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor).  By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.<ref name="insert">[https://products.sanofi.us/Zaltrap/Zaltrap.html Ziv-aflibercept (Zaltrap) package insert]</ref><ref>[[:File:Zivaflibercept.pdf|Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Diseases for which it is used==
 +
*[[Colorectal cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)] -- note: this is for Eylea, not Zaltrap<ref>[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)]</ref>
+
*[https://products.sanofi.us/Zaltrap/Zaltrap.html Ziv-aflibercept (Zaltrap) package insert].<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/ziv-aflibercept.aspx Ziv-aflibercept (Zaltrap) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/ziv-aflibercept.aspx Ziv-aflibercept (Zaltrap) patient drug information (Chemocare)]</ref>
 +
*[http://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)]</ref>
 +
 
 +
==History of changes in FDA indication==
 +
* 2012-08-31: Initial FDA approval in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]], [[Leucovorin (Folinic acid) | leucovorin]], [[Irinotecan (Camptosar) | irinotecan]] - ([[Colorectal_cancer#FOLFIRI_.26_Ziv-aflibercept| FOLFIRI]]), is indicated for patients with metastatic [[colorectal cancer]] (mCRC) that is resistant to or has progressed following an [[Regimen_classes#Oxaliplatin-based_regimen | oxaliplatin-containing regimen]]. ''(Based on VELOUR)''
 +
 
 +
==History of changes in EMA indication==
 +
*2013-02-01: Initial marketing authorization as Zaltrap.
 +
==History of changes in Health Canada indication==
 +
*2014-02-12: Initial notice of compliance
 +
==History of changes in PMDA indication==
 +
*2017-03-30: Initial approval for the treatment of unresectable advanced or recurrent [[colorectal cancer]].
 +
==Also known as==
 +
*'''Generic names:''' aflibercept, aflibercept beta, VEGF trap, ziv-aflibercept
 +
*'''Brand names:''' Zaltrap
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:VEGFR inhibitors]]
 +
[[Category:Soluble decoy receptors]]
 +
 +
[[Category:Colorectal cancer medications]]
 +
 +
[[Category:EMA approved in 2013]]
 +
[[Category:FDA approved in 2012]]
 +
[[Category:Health Canada approved in 2014]]
 +
[[Category:PMDA approved in 2017]]

Latest revision as of 12:10, 29 June 2024

General information

Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2013-02-01: Initial marketing authorization as Zaltrap.

History of changes in Health Canada indication

  • 2014-02-12: Initial notice of compliance

History of changes in PMDA indication

  • 2017-03-30: Initial approval for the treatment of unresectable advanced or recurrent colorectal cancer.

Also known as

  • Generic names: aflibercept, aflibercept beta, VEGF trap, ziv-aflibercept
  • Brand names: Zaltrap

References

  1. ↑ 1.0 1.1 1.2 Ziv-aflibercept (Zaltrap) package insert
  2. ↑ Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)
  3. ↑ Ziv-aflibercept (Zaltrap) patient drug information (Chemocare)
  4. ↑ Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Ziv-aflibercept_(Zaltrap)&oldid=87759"